Samsung Bioepis

Samsung Bioepis announces phase 3 results of SB8, Bevacizumab biosimilar candidate, at ESMO 2019 Congress
Samsung Bioepis announces phase 3 results of SB8, Bevacizumab biosimilar candidate, at ESMO 2019 Congress
Pharmaceutical Business Review
ESMO
Samsung Bioepis
clinical trials
SB8
biosimilars
bevacizumab
non-small cell lung cancer
Flag link:
FDA-approved Humira copycat from Merck, Samsung Bioepis will wait 4 years to launch
FDA-approved Humira copycat from Merck, Samsung Bioepis will wait 4 years to launch
Endpoints
Merck
Samsung Bioepis
FDA
Humira
AbbVie
drug launches
biosimilars
Flag link:
Samsung Bioepis CEO urges patience as US biosimilar market lags
Samsung Bioepis CEO urges patience as US biosimilar market lags
BioPharma Dive
biosimilars
Samsung Bioepis
Flag link:
Celltrion and Samsung duel shaping up as both pledge billions of dollars to biologics
Celltrion and Samsung duel shaping up as both pledge billions of dollars to biologics
Fierce Pharma
biologics
South Korea
Celltrion
Samsung Bioepis
Flag link:
FDA Approves 19th Biosimilar, 2nd for Enbrel
FDA Approves 19th Biosimilar, 2nd for Enbrel
RAPS.org
FDA
Samsung Bioepis
Eticovo
biosimilars
Amgen
Enbrel
Flag link:
Samsung Bioepis' First Cancer Biosimilar Approved by the FDA
Samsung Bioepis' First Cancer Biosimilar Approved by the FDA
BioSpace
FDA
Samsung Bioepis
Ontruzant
biosimilars
Genentech
Herceptin
Flag link:
FDA Approves 17th Biosimilar, Third for Herceptin
FDA Approves 17th Biosimilar, Third for Herceptin
RAPS.org
FDA
Merck
Samsung Bioepis
Ontruzant
biosimilars
Roche
Herceptin
Flag link:
Biogen Ups Investment in Biosimilar Drug Maker Samsung Bioepis by $700 Million
Biogen Ups Investment in Biosimilar Drug Maker Samsung Bioepis by $700 Million
BioSpace
Biogen
Samsung Bioepis
biosimilars
Flag link:
Battle Over Humira Begins in Europe as 5-Year Wait Begins in US
Battle Over Humira Begins in Europe as 5-Year Wait Begins in US
RAPS.org
Europe
AbbVie
Humira
Amgen
Samsung Bioepis
Mylan Labs
Novartis
Sandoz
Fresenius Kabi
Boehringer Ingelheim
Flag link:
Merck ditches biosimilar Lantus, but will that ease the path for Mylan’s rival insulin product?
Merck ditches biosimilar Lantus, but will that ease the path for Mylan’s rival insulin product?
Fierce Pharma
Merck
Samsung Bioepis
Lantus
insulin
diabetes
biosimilars
Mylan Labs
Biocon
Flag link:
Biogen goes deep into biosimilars, slapping down $700M for a major stake in Samsung Bioepis
Biogen goes deep into biosimilars, slapping down $700M for a major stake in Samsung Bioepis
Endpoints
Biogen
Samsung Bioepis
biosimilars
M&A
Flag link:
Biogen to increase stake in biosimilar developer Samsung Bioepis
Biogen to increase stake in biosimilar developer Samsung Bioepis
Biopharma Dive
Biogen
biosimilars
Samsung Bioepis
Flag link:
Janssen drops U.S. lawsuit against Samsung Bioepis' Remicade copy
Janssen drops U.S. lawsuit against Samsung Bioepis' Remicade copy
Yahoo/Reuters
Janssen
Samsung Bioepis
Remicade
biosimilars
rheumatoid arthritis
Flag link:
Samsung Bioepis first to secure EMA backing for Herceptin biosimilar
Samsung Bioepis first to secure EMA backing for Herceptin biosimilar
BioPharma Dive
Samsung Bioepis
EMA
Europe
biosimilars
Herceptin
Roche
breast cancer
Flag link:
Biogen, Samsung Humira copy wins EU approval
Biogen, Samsung Humira copy wins EU approval
Fierce Pharma
Biogen
Samsung Bioepis
Europe
Humira
AbbVie
Imraldi
biosimilars
Flag link:
Samsung Bioepis switches gears, moves from knockoffs to new drugs with fast-changing Takeda
Samsung Bioepis switches gears, moves from knockoffs to new drugs with fast-changing Takeda
Endpoints
Samsung Bioepis
Takeda
drug development
TAK-671
pancreatitis
Flag link:
Samsung Bioepis launches a Remicade knockoff at a 35% discount; FDA OK’s a self-administered version of Benlysta
Samsung Bioepis launches a Remicade knockoff at a 35% discount; FDA OK’s a self-administered version of Benlysta
Endpoints
Samsung Bioepis
Remicade
FDA
biosimilars
JNJ
GSK
Benlysta
lupus
Flag link:
EMA Recommends New HCV, Cancer and MS Drugs for Approval
EMA Recommends New HCV, Cancer and MS Drugs for Approval
RAPS.org
Europe
EMA
hepatitis C
multiple sclerosis
breast cancer
renal cell carcinoma
AbbVie
Maviret
Gilead Sciences
Vosevi
Biogen
Amgen
Samsung Bioepis
biosimilars
Humira
Novartis
Kisqali
EUSA
Fotivda
Flag link:
J&J fires off legal salvo to block Samsung's Remicade biosim launch
J&J fires off legal salvo to block Samsung's Remicade biosim launch
Fierce Pharma
JNJ
Samsung Bioepis
Remicade
biosimilar
Flag link:
Second biosimilar of Remicade approved in the US, but J&J not rattled
Second biosimilar of Remicade approved in the US, but J&J not rattled
BioPharma Dive
Remicade
JNJ
biosimilars
Renflexis
Merck
Samsung Bioepis
Flag link:

Pages